Authors: Jade Parker, Editor
Results from a pair of clinical trials evaluating the CAR-T therapy Kymriah™ (also known as CTL019) have demonstrated long-lasting remissions in non-Hodgkin’s lymphoma patients. The findings were presented recently at the 59th American Society of Hematology Annual Meeting and Exposition (December 9–12, 2017, GA, USA) and published in the New England Journal of Medicine.
In this global, multi-center trial, termed JULIET, 38%of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who received the investigational treatment had a partial or complete response at 3 months. Approximately 73% of patients who responded remained cancer-free at 6 months.